w w protein Search Results


a8194 human recombinant bcl w novusbiologicals  (Novus Biologicals)
90
Novus Biologicals a8194 human recombinant bcl w novusbiologicals
A8194 Human Recombinant Bcl W Novusbiologicals, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a8194 human recombinant bcl w novusbiologicals/product/Novus Biologicals
Average 90 stars, based on 1 article reviews
a8194 human recombinant bcl w novusbiologicals - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
human recombinant bcl 2 proteins  (R&D Systems)
91
R&D Systems human recombinant bcl 2 proteins
Human Recombinant Bcl 2 Proteins, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human recombinant bcl 2 proteins/product/R&D Systems
Average 91 stars, based on 1 article reviews
human recombinant bcl 2 proteins - by Bioz Stars, 2026-04
91/100 stars
  Buy from Supplier
western blotting human recombinant trail  (R&D Systems)
91
R&D Systems western blotting human recombinant trail
Western Blotting Human Recombinant Trail, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/western blotting human recombinant trail/product/R&D Systems
Average 91 stars, based on 1 article reviews
western blotting human recombinant trail - by Bioz Stars, 2026-04
91/100 stars
  Buy from Supplier
tbs t  (Boster Bio)
93
Boster Bio tbs t
Tbs T, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tbs t/product/Boster Bio
Average 93 stars, based on 1 article reviews
tbs t - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
bcl w  (Sino Biological)
93
Sino Biological bcl w
Bcl W, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bcl w/product/Sino Biological
Average 93 stars, based on 1 article reviews
bcl w - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
anti ndufs8 antibodies  (Boster Bio)
93
Boster Bio anti ndufs8 antibodies
Fig. 8. Validation of cuproptosis and key genes in STZ-induced diabetic mice. (A, B) WB and quantitative analyses were conducted to assess the expression levels of cuproptosis-characterizing proteins (FDX1, DLAT, and <t>NDUFS8)</t> in diabetic and non-diabetic retinas at 6, 8, 12, or 14 weeks following diabetes induction (ns P＞0.05, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, one-way ANOVA, n ≥3). (C-E) WB and quantitative analyses were conducted to assess STAT1 and SLC31A1 expression levels in diabetic and non-diabetic retinas at 6, 8, 12, or 14 weeks following diabetes induction (ns P＞0.05, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, one-way ANOVA, n ≥3). (F) Immunofluorescence demonstrating co-expression of SLC31A1 (green) with IBA1 (gold), indicating microglia. Scale bar, 50 μm.
Anti Ndufs8 Antibodies, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti ndufs8 antibodies/product/Boster Bio
Average 93 stars, based on 1 article reviews
anti ndufs8 antibodies - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
bcl w catalog 824 bw 050  (R&D Systems)
90
R&D Systems bcl w catalog 824 bw 050
Fig. 8. Validation of cuproptosis and key genes in STZ-induced diabetic mice. (A, B) WB and quantitative analyses were conducted to assess the expression levels of cuproptosis-characterizing proteins (FDX1, DLAT, and <t>NDUFS8)</t> in diabetic and non-diabetic retinas at 6, 8, 12, or 14 weeks following diabetes induction (ns P＞0.05, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, one-way ANOVA, n ≥3). (C-E) WB and quantitative analyses were conducted to assess STAT1 and SLC31A1 expression levels in diabetic and non-diabetic retinas at 6, 8, 12, or 14 weeks following diabetes induction (ns P＞0.05, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, one-way ANOVA, n ≥3). (F) Immunofluorescence demonstrating co-expression of SLC31A1 (green) with IBA1 (gold), indicating microglia. Scale bar, 50 μm.
Bcl W Catalog 824 Bw 050, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bcl w catalog 824 bw 050/product/R&D Systems
Average 90 stars, based on 1 article reviews
bcl w catalog 824 bw 050 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
structural basis for importin alpha 3 specificity of w proteins in hendra and nipah viruses  (Basler)
90
Basler structural basis for importin alpha 3 specificity of w proteins in hendra and nipah viruses
Fig. 8. Validation of cuproptosis and key genes in STZ-induced diabetic mice. (A, B) WB and quantitative analyses were conducted to assess the expression levels of cuproptosis-characterizing proteins (FDX1, DLAT, and <t>NDUFS8)</t> in diabetic and non-diabetic retinas at 6, 8, 12, or 14 weeks following diabetes induction (ns P＞0.05, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, one-way ANOVA, n ≥3). (C-E) WB and quantitative analyses were conducted to assess STAT1 and SLC31A1 expression levels in diabetic and non-diabetic retinas at 6, 8, 12, or 14 weeks following diabetes induction (ns P＞0.05, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, one-way ANOVA, n ≥3). (F) Immunofluorescence demonstrating co-expression of SLC31A1 (green) with IBA1 (gold), indicating microglia. Scale bar, 50 μm.
Structural Basis For Importin Alpha 3 Specificity Of W Proteins In Hendra And Nipah Viruses, supplied by Basler, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/structural basis for importin alpha 3 specificity of w proteins in hendra and nipah viruses/product/Basler
Average 90 stars, based on 1 article reviews
structural basis for importin alpha 3 specificity of w proteins in hendra and nipah viruses - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
mpc 80%, w/w, protein  (Fonterra Co operative Group Limited)
90
Fonterra Co operative Group Limited mpc 80%, w/w, protein
Fig. 8. Validation of cuproptosis and key genes in STZ-induced diabetic mice. (A, B) WB and quantitative analyses were conducted to assess the expression levels of cuproptosis-characterizing proteins (FDX1, DLAT, and <t>NDUFS8)</t> in diabetic and non-diabetic retinas at 6, 8, 12, or 14 weeks following diabetes induction (ns P＞0.05, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, one-way ANOVA, n ≥3). (C-E) WB and quantitative analyses were conducted to assess STAT1 and SLC31A1 expression levels in diabetic and non-diabetic retinas at 6, 8, 12, or 14 weeks following diabetes induction (ns P＞0.05, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, one-way ANOVA, n ≥3). (F) Immunofluorescence demonstrating co-expression of SLC31A1 (green) with IBA1 (gold), indicating microglia. Scale bar, 50 μm.
Mpc 80%, W/W, Protein, supplied by Fonterra Co operative Group Limited, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mpc 80%, w/w, protein/product/Fonterra Co operative Group Limited
Average 90 stars, based on 1 article reviews
mpc 80%, w/w, protein - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
protein m.w. markers  (Double Helix)
90
Double Helix protein m.w. markers
Fig. 8. Validation of cuproptosis and key genes in STZ-induced diabetic mice. (A, B) WB and quantitative analyses were conducted to assess the expression levels of cuproptosis-characterizing proteins (FDX1, DLAT, and <t>NDUFS8)</t> in diabetic and non-diabetic retinas at 6, 8, 12, or 14 weeks following diabetes induction (ns P＞0.05, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, one-way ANOVA, n ≥3). (C-E) WB and quantitative analyses were conducted to assess STAT1 and SLC31A1 expression levels in diabetic and non-diabetic retinas at 6, 8, 12, or 14 weeks following diabetes induction (ns P＞0.05, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, one-way ANOVA, n ≥3). (F) Immunofluorescence demonstrating co-expression of SLC31A1 (green) with IBA1 (gold), indicating microglia. Scale bar, 50 μm.
Protein M.W. Markers, supplied by Double Helix, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/protein m.w. markers/product/Double Helix
Average 90 stars, based on 1 article reviews
protein m.w. markers - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
m.w. standards 14 c methylated proteins, 220 kda-14·3 kda  (Amersham Life Sciences Inc)
90
Amersham Life Sciences Inc m.w. standards 14 c methylated proteins, 220 kda-14·3 kda
Fig. 8. Validation of cuproptosis and key genes in STZ-induced diabetic mice. (A, B) WB and quantitative analyses were conducted to assess the expression levels of cuproptosis-characterizing proteins (FDX1, DLAT, and <t>NDUFS8)</t> in diabetic and non-diabetic retinas at 6, 8, 12, or 14 weeks following diabetes induction (ns P＞0.05, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, one-way ANOVA, n ≥3). (C-E) WB and quantitative analyses were conducted to assess STAT1 and SLC31A1 expression levels in diabetic and non-diabetic retinas at 6, 8, 12, or 14 weeks following diabetes induction (ns P＞0.05, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, one-way ANOVA, n ≥3). (F) Immunofluorescence demonstrating co-expression of SLC31A1 (green) with IBA1 (gold), indicating microglia. Scale bar, 50 μm.
M.W. Standards 14 C Methylated Proteins, 220 Kda 14·3 Kda, supplied by Amersham Life Sciences Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/m.w. standards 14 c methylated proteins, 220 kda-14·3 kda/product/Amersham Life Sciences Inc
Average 90 stars, based on 1 article reviews
m.w. standards 14 c methylated proteins, 220 kda-14·3 kda - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
fragment peptide 35–55 of the mog protein (m q v g w y a s p f s a v v h ly a n g k)  (GenScript corporation)
90
GenScript corporation fragment peptide 35–55 of the mog protein (m q v g w y a s p f s a v v h ly a n g k)
Fig. 8. Validation of cuproptosis and key genes in STZ-induced diabetic mice. (A, B) WB and quantitative analyses were conducted to assess the expression levels of cuproptosis-characterizing proteins (FDX1, DLAT, and <t>NDUFS8)</t> in diabetic and non-diabetic retinas at 6, 8, 12, or 14 weeks following diabetes induction (ns P＞0.05, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, one-way ANOVA, n ≥3). (C-E) WB and quantitative analyses were conducted to assess STAT1 and SLC31A1 expression levels in diabetic and non-diabetic retinas at 6, 8, 12, or 14 weeks following diabetes induction (ns P＞0.05, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, one-way ANOVA, n ≥3). (F) Immunofluorescence demonstrating co-expression of SLC31A1 (green) with IBA1 (gold), indicating microglia. Scale bar, 50 μm.
Fragment Peptide 35–55 Of The Mog Protein (M Q V G W Y A S P F S A V V H Ly A N G K), supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fragment peptide 35–55 of the mog protein (m q v g w y a s p f s a v v h ly a n g k)/product/GenScript corporation
Average 90 stars, based on 1 article reviews
fragment peptide 35–55 of the mog protein (m q v g w y a s p f s a v v h ly a n g k) - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Fig. 8. Validation of cuproptosis and key genes in STZ-induced diabetic mice. (A, B) WB and quantitative analyses were conducted to assess the expression levels of cuproptosis-characterizing proteins (FDX1, DLAT, and NDUFS8) in diabetic and non-diabetic retinas at 6, 8, 12, or 14 weeks following diabetes induction (ns P＞0.05, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, one-way ANOVA, n ≥3). (C-E) WB and quantitative analyses were conducted to assess STAT1 and SLC31A1 expression levels in diabetic and non-diabetic retinas at 6, 8, 12, or 14 weeks following diabetes induction (ns P＞0.05, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, one-way ANOVA, n ≥3). (F) Immunofluorescence demonstrating co-expression of SLC31A1 (green) with IBA1 (gold), indicating microglia. Scale bar, 50 μm.

Journal: Gene

Article Title: The STAT1-SLC31A1 axis: Potential regulation of cuproptosis in diabetic retinopathy.

doi: 10.1016/j.gene.2024.148861

Figure Lengend Snippet: Fig. 8. Validation of cuproptosis and key genes in STZ-induced diabetic mice. (A, B) WB and quantitative analyses were conducted to assess the expression levels of cuproptosis-characterizing proteins (FDX1, DLAT, and NDUFS8) in diabetic and non-diabetic retinas at 6, 8, 12, or 14 weeks following diabetes induction (ns P＞0.05, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, one-way ANOVA, n ≥3). (C-E) WB and quantitative analyses were conducted to assess STAT1 and SLC31A1 expression levels in diabetic and non-diabetic retinas at 6, 8, 12, or 14 weeks following diabetes induction (ns P＞0.05, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, one-way ANOVA, n ≥3). (F) Immunofluorescence demonstrating co-expression of SLC31A1 (green) with IBA1 (gold), indicating microglia. Scale bar, 50 μm.

Article Snippet: The primary antibodies used to incubate each membrane at 4°C for a whole night include anti-SLC31A1 (Abclona; cat no. A0773; 1:1000), antiSTAT1 (ProteinTech; cat no. 10144-2-AP; 1:1000), anti-DLAT (Abclona; cat no. A14530; 1:1000), anti-FDX1 (Abclona; cat no. A20895; 1:1000), and anti-NDUFS8 antibodies (Boster Bio; cat no. A08275-2; 1:1000).

Techniques: Biomarker Discovery, Expressing, Immunofluorescence

Fig. 9. Validation of cuproptosis and key genes in the in vitro model. (A) Comparative expression analysis of eight cuproptosis-related DEGs between NG and HG conditions for 48 h in BV2 cells was performed via RT-qPCR assays (ns P＞0.05,*P<0.05, **P<0.01, ***P<0.001, t-test, n ≥3). (B) Correlation analysis of SLC31A1 and STAT1 in GSE102485. (C–H) WB and quantitative analyses were performed to determine the expression levels of cuproptosis-characterizing proteins (FDX1, DLAT, and NDUFS8) and key genes (STAT1 and SLC31A1) between NG and HG conditions for 24 or 48 h in BV2 cells (ns P＞0.05,*P<0.05, **P<0.01, one- way ANOVA, n ≥3). (I) Images exemplifying immunofluorescence staining of SLC31A1 (red) or phalloidin (green) to detect subcellular localization of SLC31A1. Scale bar, 125 μm.

Journal: Gene

Article Title: The STAT1-SLC31A1 axis: Potential regulation of cuproptosis in diabetic retinopathy.

doi: 10.1016/j.gene.2024.148861

Figure Lengend Snippet: Fig. 9. Validation of cuproptosis and key genes in the in vitro model. (A) Comparative expression analysis of eight cuproptosis-related DEGs between NG and HG conditions for 48 h in BV2 cells was performed via RT-qPCR assays (ns P＞0.05,*P<0.05, **P<0.01, ***P<0.001, t-test, n ≥3). (B) Correlation analysis of SLC31A1 and STAT1 in GSE102485. (C–H) WB and quantitative analyses were performed to determine the expression levels of cuproptosis-characterizing proteins (FDX1, DLAT, and NDUFS8) and key genes (STAT1 and SLC31A1) between NG and HG conditions for 24 or 48 h in BV2 cells (ns P＞0.05,*P<0.05, **P<0.01, one- way ANOVA, n ≥3). (I) Images exemplifying immunofluorescence staining of SLC31A1 (red) or phalloidin (green) to detect subcellular localization of SLC31A1. Scale bar, 125 μm.

Article Snippet: The primary antibodies used to incubate each membrane at 4°C for a whole night include anti-SLC31A1 (Abclona; cat no. A0773; 1:1000), antiSTAT1 (ProteinTech; cat no. 10144-2-AP; 1:1000), anti-DLAT (Abclona; cat no. A14530; 1:1000), anti-FDX1 (Abclona; cat no. A20895; 1:1000), and anti-NDUFS8 antibodies (Boster Bio; cat no. A08275-2; 1:1000).

Techniques: Biomarker Discovery, In Vitro, Expressing, Quantitative RT-PCR, Immunofluorescence, Staining